The global nuclear medicine market is projected to grow from USD 8.42 billion in 2023 to USD 29.35 billion by 2030, with a compound annual growth rate (CAGR) of 19.5% during the forecast period. Nuclear medicine, which involves the use of radioactive drugs for diagnosis and therapy, is gaining prominence in clinical areas such as neurology, cardiology, and oncology. The market is driven by the rising prevalence of chronic diseases and advancements in technology that enable the effective use of radiopharmaceuticals for diagnosing and treating cancerous tumors. Key players in the market include Lantheus Medical Imaging, Cardinal Health, Norgine, Nordion, Bayer, Curium, Advanced Accelerator Applications, Bracco Diagnostic, Jubilant Pharmova, and GE Healthcare. The diagnostic segment dominates the market, fueled by efficient imaging techniques and new product launches. The oncology segment is projected to exhibit the highest growth rate due to the increasing prevalence of cancer and the development of pipeline products for nuclear medicine therapies. The market is led by North America, followed by Europe, with key players focusing on new product launches, acquisitions, and research and development initiatives to gain a strong market share.
Thu, 10 Aug 2023 11:28:00 GMT | GlobeNewswire